Tom3 schreef op 31 maart 2022 22:12:
Uit de conference call van vandaag (Harstrick), let even niet op de spelfouten, gezien op Seeking Alpha :
"We are very excited that the abstract submitted to AACR by MD Anderson Cancer Center and [Indiscernible] for study AFM13-104 has been accepted at a very prominent place for oral presentation and the clinical trials plenary session. This session will be hosted from 1:00 PM to 3:00 PM on Sunday, April 10th In addition to MD Anderson, presentation will also be featured at the AACR press conference on Sunday, April 10th.
It's this AACR presentation, jago and yet Joe from MD Anderson due principally investigator of the trial, will provide updates on the first 19 patients enrolled in the study. Of Note, the update will include the response rates, overall response right? And complete response rate for those 13 patients treated at the recommended Phase II dose. Now, after two cycles of therapy, and was also show additional follow-up data as compared to the data presented in December. As you know, we have seen some evidence. Also deepening of responses at the lower dose cohorts between cycles one and cycles two. And therefore, the final response right after two cycles of therapy four patients at the recommended Phase II dose will allow a very good assessment of Citigroup potency offices treatment.
seekingalpha.com/article/4499033-affi...Als iets een prominente plaats op een belangrijk congres inneemt verwacht ik geen deceptie.